POSTER'18'
OUR'EXPERIENCE'IN'GASTRIC'MALT'LYMPHOMA'
'
Maria! Eduarda! Couto1,! Isabel! Oliveira1,! Nelson! Domingues1,! Luisa! Viterbo1,! Angelo! Martins1,! Ilídia!
Moreira1,! Ana! EspiritoJSanto1,! Sérgio! Chacim1,! Cláudia! Moreira1,! Dulcineia! Pereira1,! Rui!
Henrique2!and!José!Mariz1!
!
(1)OncoUhematology!Service,!Instituto!Português!de!Oncologia!do!Porto,!F.G.,!E.P.E.,!Porto,!Portugal,!
(2)Pathology!Service,!Instituto!Portugues!de!Oncologia!do!Porto,!F.G.,!E.P.E.,!Porto,!Portugal!
!
Gastric! mucosa! associated! lymphoid! tissue! nonJHodgkin! lymphoma! (gMALT! NHL)! is! the!
second! most! common! gastrointestinal! lymphoma! (50%! of! all! gastric! lymphomas),! being!
closely! associated! with!Helicobacter! pylori!infection,! justifying! that! antibiotic! therapy! is!
effective!in!50!to!70%!of!all!cases.!
This!is!a!retrospective!and!unicenter!study!analyzing!all!adult!gMALT!NHL!cases!diagnosed!
and! treated! along! 8! years! (2011J2018),! focusing! on! demographic! features,! treatment!
outcomes!and!survival!analysis.!
Sixty! patients! with! a! median! age! of! 61! years! (53.3%! with! female! gender)! were! analyzed.!
Most! of! the! cases! had! localized! disease! (66.7%! were! in! Lugano! stage! I)! and! had! low! IPI!
scores! (median:! 1).! There! was! a! high! prevalence! of!Helicobacter! pylori!infection! (68.3%).!
Nearly!97%!of!the!cases!received!treatment!for!the!disease,!a!median!of!one!line;!55%!of!the!
patients! treated! endured! complete! response! after! first! line! therapy! (mostly!
antibiotics).!Median!overall!survival!time!and!median!progression!free!survival!time!were!not!
reached.!The!mean!survival!time!was!81.8!73.3J90.3!months.!ThirtyJsix!patients!(60%)!had!
a! 3Jyear! followJup! time.!Age! superior! to! 65! years! and! transformation! into! DLBCL! were!
statistically! significant! negative! prognostic! markers! for! survival! in! this! study! (p=0.006! and!
p=0.033,!respectively).!
Our! study! confirms! that! gMALT! NHL! is! an! indolent! disease! with! long! term! survival.! Many!
patients,!however,!are!exposed!to!several!treatment!lines!along!the!course!of!disease.!
! !
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES